Drug Trial Radar · NCT00313911
Safety of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Tritanrix-HepB/Hib™ and OPV Given at Age 2, 4, and 6 Months.
Last checked: Nov 20, 2026Latest source record: Apr 21, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,133
Actual
Start
Jul 2006
Primary completion
Jan 2008
Study completion Feb 2008
Sponsor
- Lead sponsor
- Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Apr 12, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 50 days, up to 71 days
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To demonstrate that DTaP-IPV-HB-PRP\~T combined vaccine does not induce a higher incidence rate of high fever than Tritanrix-HepB/Hib™ and Oral Polio Vaccine (OPV) after any of the three vaccinations at 2, 4, and 6 months of age for each subject. To evaluate the overall safety in terms of: Any solicited adverse reactions in the first 7 days after each injection, Any adverse events and reactions in the first 30 days after each injection, Any serious adverse events during the trial. Immunogenicity: To document the immune response to Hepatitis B antigen of the three batches of the investigational DTaP-IPV-HB-PRP\~T vaccine.
Conditions
- Diphtheria
- Tetanus
- Pertussis
- Haemophilus Influenzae Type b
- Hepatitis B
Interventions
DTaP-IPV-HB-PRP~TBiological
0.5 mL, Intramuscular (IM)
Tritanrix-HepB/HibBiological
0.5 mL, Intramuscular
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With High Fever Observed After Either DTaP-IPV-Hep B-PRP~T or Tritanrix Hep B/Hib™ + Placebo or Tritanrix-Hep B/Hib™ + Placebo Injection.Time frame: Day 0 up to Day 7 post-injection
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
Site not named
Mexico City, Mexico
Site not named
Lima, Peru
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.